Previous 10 | Next 10 |
Tyme Technologies (NASDAQ: TYME ) +29% as oncology research reveals potential new oral therapy TYME-19 in the fight against COVID-19. More news on: Tyme Technologies, Inc., SCWorx Corp., Immunic, Inc., Stocks on the move, , Read more ...
Fluidigm (NASDAQ: FLDM ) has received Emergency Use Authorization (EUA) from the FDA for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS‑CoV‑2 virus, designed to be run on the Fluidigm Biomark HD m...
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Ca...
Fluidigm Corporation (FLDM) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Agnes Lee – Vice President-Investor Relations Chris Linthwaite – President and Chief Executive Officer Vikram Jog – Chief Financial Officer Conferen...
The following slide deck was published by Fluidigm Corporation in conjunction with their 2020 Q2 earnings Read more ...
Fluidigm (NASDAQ: FLDM ) : Q2 Non-GAAP EPS of -$0.07 beats by $0.07 ; GAAP EPS of -$0.18 beats by $0.05 . More news on: Fluidigm Corporation, Earnings news and commentary, Tech stocks news, Read more ...
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected...
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a distribution agreement with De Novo Software™ to provid...
Fluidigm receives NIH funding for COVID-19 testing technology Fluidigm Corporation ( FLDM ) announced that it has inked a letter contract with the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering. The contract pertains to a probable project under...
Shares of Fluidigm (NASDAQ: FLDM) rose over 58% today after the company announced it was selected to receive up to $37 million from the National Institutes of Health through the agency's Rapid Acceleration of Diagnostics (RADx) program. The funding is intended to develop methods for expandin...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...